Recycling Enfuvirtide: Possible Clinical Benefit

Salvage therapy that included enfuvirtide appeared to show a survival benefit in a small, uncontrolled, retrospective study of HIV-positive patients who had already experienced virologic failure on an enfuvirtide-containing regimen.

The fusion inhibitor enfuvirtide is among the more recent options to include in a salvage regimen for HIV-positive patients who have resistance to multiple antiretroviral drugs. Although data on virologic suppression with enfuvirtide are promising, clinical benefits are less clear, particularly in the context of reintroducing (i.e., recycling) the drug to patients who have previously experienced virologic failure on an enfuvirtide-containing regimen.

Researchers retrospectively studied outcomes in 32 patients who had experienced virologic failure (viral load, >400 copies/mL) after using an enfuvirtide-containing regimen for at least 6 months. After a minimum of 30 days off the initial regimen, 17 of the patients recycled enfuvirtide in a new…

Reviewing Author

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

Recycling Enfuvirtide: Possible Clinical Benefit

Topics

Reviewing Author